OnCo
technologiesTechnologyEstablished

AlphaFold 3

Predicts the 3D shape of proteins together with DNA, RNA, small molecules and antibodies, the starting point for much modern drug design.

Nature 2024 (DeepMind and Isomorphic); diffusion-based joint structure prediction; weights released for academic use late 2024. Isomorphic uses successors commercially.

Generic schematic · not to scale · placeholder for the drug discovery front
Guide RNA library · Knockout → dependency

How it works

AlphaFold 3 combines a Pairformer with a diffusion module over all biomolecular types.

Strengths
  • Complexes and ligands
Limitations
  • Static structures; antibody-antigen accuracy still limited
Since
2024

Key papers

1top
methodsNature 2021
AlphaFold 2: predicting protein structures to near-experimental accuracy

The shape of nearly every protein is now available to any researcher in seconds instead of years, which shortens the path from a cancer target to a designed molecule. It does not by itself produce drugs: binding pockets, dynamics and cellular context still need experiment.

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"AlphaFold 3" OR ABSTRACT:"AlphaFold 3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AlphaFold 3, not a curated reading list.

Connected

6top

fronts

2
AI & ComputationDrug Discovery Platforms

technologies

1
AI-driven drug & target discovery

companies

2
Google DeepMind (and Google Research)Isomorphic Labs

key papers

1
AlphaFold 2: predicting protein structures to near-experimental accuracy